SCHEMBL8584996

SCHEMBL8584996

COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@](O)(C(=O)C(C)(C)C)[C@@H]1O

nearest known ligand 0.44

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NT5E P21589 5/20 0.41
CYP2C19 P33261 1/20 0.41
ADORA2A P29274 3/20 0.41
ADORA3 P0DMS8 2/20 0.41
ADORA1 P30542 2/20 0.41
ADORA2B P29275 2/20 0.41
HSP90B1 P14625 1/20 0.39
SLC29A1 Q99808 3/20 0.39
HINT1 P49773 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8586292 0.85 NT5E (0.42) NT5ECYP2C19ADORA2AADORA3ADORA1
SCHEMBL8587172 0.84 ADORA2A (0.47) CYP2C19ADORA2AADORA3ADORA1ADORA2B
SCHEMBL31367285 0.81 HINT1 (0.49) NT5EADORA3HINT1
SCHEMBL16125688 0.76 ADORA2A (0.45) CYP2C19ADORA2AADORA3ADORA1ADORA2B
SCHEMBL8529892 0.76 CYP2C19 (0.52) CYP2C19ADORA2AADORA3ADORA1ADORA2B
SCHEMBL8532515 0.76 CYP2C19 (0.52) CYP2C19ADORA2AADORA3ADORA1ADORA2B
SCHEMBL8587367 0.76 ADORA2A (0.41) CYP2C19ADORA2AADORA3ADORA1ADORA2B
SCHEMBL8588424 0.75 ADORA3 (0.42) NT5ECYP2C19ADORA2AADORA3ADORA1
Nelarabine SCHEMBL18820 0.74 CYP2C19 (0.71) NT5ECYP2C19ADORA2AADORA3ADORA1
Nelarabine SCHEMBL20769831 0.74 CYP2C19 (0.71) NT5ECYP2C19ADORA2AADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998042352-A1 METHOD FOR TREATING B-CELL TUMORS WITH ARA-G NUCLEOSIDE DERIVATIVES GLAXO GROUP LTD. (GB) 1998-10-01 WO disclosed
WO-1992001456-A1 HETEROCYCLIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1992-02-06 WO disclosed